AMGN

SEC source: 0001127602-20-019949 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,576

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 1,913 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-019949 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,576

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-017431 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 1,000 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-017431 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,482

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 1,819 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-017431 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-015857 · form4.xml · nonDerivative · entry 2

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,409

F2 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

SEC source: 0001127602-20-015844 · form4.xml · nonDerivative · entry 1

Austin Wanda M · CIK 0001690882 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,194

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSU's may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

SEC source: 0001127602-20-015846 · form4.xml · nonDerivative · entry 1

Druker Brian · CIK 0001740205 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,719

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015847 · form4.xml · nonDerivative · entry 1

ECKERT ROBERT · CIK 0001194256 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,031

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 1,156 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015850 · form4.xml · nonDerivative · entry 1

Garland Greg C. · CIK 0001503107 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,024

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested imediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-20-015851 · form4.xml · nonDerivative · entry 1

Hassan Fred · CIK 0001110744 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,191

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-20-015852 · form4.xml · nonDerivative · entry 1

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,973.6942

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 1,849 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan, and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015853 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,974.5251

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 125 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015854 · form4.xml · nonDerivative · entry 1

Jacks Tyler · CIK 0001464237 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,302

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Plan) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 817 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015855 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,380.1559

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

F2 · balance_after: These shares include 252 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015856 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,482

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 1,819 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015857 · form4.xml · nonDerivative · entry 1

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,834

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-20-015858 · form4.xml · derivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,031

Underlying: Common Stock · 102,031 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015858 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 543,966

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 5,019 RSUs which vest on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023; and 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,468 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015859 · form4.xml · derivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,050

Underlying: Common Stock · 29,050 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015859 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,873

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 22,238 RSUs which vest in installments of 11,975 on 11/2/2020 and 10,263 on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,145 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015860 · form4.xml · derivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,633

Underlying: Common Stock · 27,633 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015860 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,656

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015861 · form4.xml · derivative · entry 2

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,341

Underlying: Common Stock · 28,341 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015861 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,990

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 18,352 RSUs which vest in two installments of 6,056 on each of 11/1/2021 and 11/1/2022 and one installment of 6,240 on 11/1/2023; and 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 254 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-20-015862 · form4.xml · derivative · entry 2

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,799

Underlying: Common Stock · 24,799 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015862 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,268

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 422 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015863 · form4.xml · derivative · entry 3

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,668

Underlying: Common Stock · 5,668 shares

Expires 2030-05-05

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015863 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,751

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 604 RSUs which vest in installments of 297 on 4/27/2021 and 307 on 4/27/2022; 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023; and 676 RSUs which vest in two installments of 223 on 5/5/2022 and 5/5/2023, and one installment of 230 on 5/5/2024.. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015864 · form4.xml · derivative · entry 2

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,628

Underlying: Common Stock · 10,628 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015864 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,773

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-20-015865 · form4.xml · derivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,050

Underlying: Common Stock · 29,050 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015865 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,408

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 926 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015866 · form4.xml · derivative · entry 3

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,341

Underlying: Common Stock · 28,341 shares

Expires 2030-05-05

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015866 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,433

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 3,905 RSUs which vest on 8/1/2020; 1,171 RSUs which vest on 5/1/2021; 2,114 RSUs which vest in installments of 1,041 on 4/27/2021 and 1,073 on 4/27/2022; 3,947 RSUs which will vest in installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,342 on 5/3/2023; and 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 774 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015542 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 531,782

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,019 RSUs which vest on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; and 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,468 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015544 · form4.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,356

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015548 · form4.xml · nonDerivative · entry 2

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,075

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 604 RSUs which vest in installments of 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015551 · form4.xml · nonDerivative · entry 2

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,504

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-20-015556 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,939

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which vest on 5/1/2021; 335 RSUs which vest on 5/1/2021; 680 RSUs which vest in installments of 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 926 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015558 · form4.xml · nonDerivative · entry 2

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,049

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,905 RSUs which vest on 8/1/2020; 1,171 RSUs which vest on 5/1/2021; 2,114 RSUs which vest in installments of 1,041 on 4/27/2021 and 1,073 on 4/27/2022; and 3,947 RSUs which will vest in installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,342 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 774 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015542 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 534,541

SEC source: 0001127602-20-015544 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,911

SEC source: 0001127602-20-015546 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,307

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; and 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 422 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015548 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,202

SEC source: 0001127602-20-015551 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,640

SEC source: 0001127602-20-015556 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,124

SEC source: 0001127602-20-015558 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,243

SEC source: 0001127602-20-014694 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 537,278

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,784 RSUs which vest on 5/3/2020; 9,890 RSUs which vest in installments of 4,871 on 5/1/2020 and 5,019 on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; and 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 2,455 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-014695 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,460

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 644 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.